The recommendation is specifically for adults with the immune-mediated inflammatory bowel disease, for whom conventional or biologic treatments cannot be tolerated, or for those who have found that the condition has not responded well enough or have stopped responding to treatments.
NICE’s decision is based on data taken from the induction studies, U-ACHIEVE and U-ACCOMPLISH, as well as the phase 3 U-ACHIEVE maintenance study and covers treatment access for patients in England and Wales. The three studies showed the efficacy of Rinvoq compared to placebo in its ability to achieve clinical remission at weeks eight and 52…
